Marksans Pharma has announced its standalone unaudited financial results for the quarter and half-year ended September 30, 2026. The company reported a profit after tax of ₹855.42 crore for the quarter and ₹1,545.79 crore for the half-year. The results, which were approved by the Board of Directors, also include limited review reports from statutory auditors MSKA & Associates LLP, who expressed an unmodified opinion.
Marksans Pharma Announces Q2 FY27 Financial Results
Marksans Pharma Ltd. has disclosed its standalone unaudited financial results for the quarter and half-year ended September 30, 2026. The company’s Board of Directors approved these results at a meeting held on November 04, 2026.
Key Financial Highlights (Standalone)
Quarter Ended September 30, 2026:
- Revenue from operations: ₹3,138.04 million
- Other income, net: ₹572.43 million
- Total Income: ₹3,710.47 million
- Total Expenses: ₹2,708.34 million
- Profit Before Tax: ₹1,002.13 million
- Profit After Tax: ₹855.42 million
- Total Comprehensive Income: ₹858.02 million
Half Year Ended September 30, 2026:
- Revenue from operations: ₹6,349.91 million
- Other income, net: ₹581.89 million
- Total Income: ₹7,097.04 million
- Total Expenses: ₹5,190.33 million
- Profit Before Tax: ₹1,906.71 million
- Profit After Tax: ₹1,545.79 million
- Total Comprehensive Income: ₹1,550.99 million
Auditor’s Report
M/s. MSKA & Associates LLP, Chartered Accountants, the Statutory Auditors of the Company, have submitted their Limited Review Reports for the Unaudited Financial Results (Standalone and Consolidated) with an unmodified opinion. The meeting to review these results commenced at 12:10 p.m. and concluded at 01:20 p.m. on November 04, 2026.
Consolidated Financial Overview
The consolidated financial results for the quarter and half-year ended September 30, 2026, also reflect the performance of the Group. For the quarter ended September 30, 2026, the consolidated profit after tax stood at ₹1,435.25 million, and for the half-year ended the same date, it was ₹3,029.32 million. The consolidated total comprehensive income for the quarter and half-year were ₹1,737.17 million and ₹3,501.48 million, respectively.
Business Developments
During the half-year ended September 30, 2026, Marksans Pharma acquired 100% share capital of QliniQ B.V., a Netherlands-based company specializing in innovative healthcare solutions. Additionally, in the quarter ended September 30, 2026, the company acquired 100% share capital of ABCnow GmbH, a Germany-based pharmaceutical company. Furthermore, 300,000 stock options were granted to eligible employees under the Marksans Employees Stock Option Scheme 2024.
Source: BSE
